April 26th 2024
The clearance of the IND application for RAG-01 will initiate the launch of clinical trials in the US.
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Impact of cisplatin ineligibility on receiving adjuvant therapy for UTUC
February 15th 2022Shawn Dason, MD, discusses the findings and takeaways of the study, "How often does cisplatin ineligibility prevent patients from receiving adjuvant therapy following radical nephroureterectomy for upper tract urothelial carcinoma?"
Study demonstrates feasibility of antegrade instillation of Jelmyto for UTUC
February 11th 2022“While Jelmyto is approved for both retrograde and antegrade instillation, the instructions for administration address retrograde instillation, and this is the first time that data on antegrade instillation has been documented in a clinical setting for this chemoablative therapy,” said Katie Murray, DO.
Gender disparities found in bladder cancer trials and real-world systemic therapy use
February 8th 2022“We have to be more mindful and thoughtful about the fact that certain populations are underrepresented in clinical trials, and that’s likely due to a number of factors,” said co-author Padraic O’Malley, MD, MSc, FRCSC.
Final report of the OLYMPUS Jelmyto trial: Takeaways for urologists
January 24th 2022“I think that these data firmly establish UGN-101, or Jelmyto, as a bona fide treatment option for kidney preservation for patients with low-grade, non-invasive urothelial cancer in the upper urinary tract,” says Seth P. Lerner, MD.
Dr. Bupathi discusses JAVELIN Bladder 100 trial of maintenance avelumab
January 13th 2022In the study, adding maintenance avelumab to best supportive care (BSC) led to a 31% reduction in the risk of death versus BSC alone in patients with unresectable locally advanced or metastatic urothelial cancer.